Chemotherapy and Immunotherapy for Head and Neck Cancer That Has Returned
Part of Cancer clinical trials.
This trial is testing whether giving a combination of chemotherapy drugs directly into the tumor along with an immunotherapy drug called nivolumab given through an IV can help when head or neck cancer has come back in the same area. The goal is to control the local tumor when other standard treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to do normal activities (fully active, up and about, or limited in strenuous work but not in light work).
- Your head or neck cancer must have come back in the same area after standard treatments like surgery, radiation, chemotherapy, or the drug cetuximab.
- You must have already tried the immunotherapy drug nivolumab and it wasn't effective enough.
- Your doctor needs to be able to see the tumor on a scan or exam (and if it has spread, that must not be life-threatening).
- Your blood counts and liver and kidney function must be within safe limits (your doctor will check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests an immunotherapy given after salvage surgery for certain head and neck squamous cell cancers that came back (or a new second cancer) in an area that was already treated with radiation. It aims to lower the chance the cancer returns after surgery, especially in higher-risk situations.
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a drug called anti-PD-1 (an immunotherapy that helps your immune system attack cancer) for people whose head and neck cancer has returned or spread but can still be removed with surgery. The goal is to see if this treatment helps control the cancer better.
Hear when a new Paclitaxel trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.